A061250 Stock Overview
Develops pharmaceutical raw materials in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Hwail Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,214.00 |
| 52 Week High | ₩2,280.00 |
| 52 Week Low | ₩1,150.00 |
| Beta | 0 |
| 11 Month Change | -12.35% |
| 3 Month Change | -27.31% |
| 1 Year Change | -39.24% |
| 33 Year Change | -50.75% |
| 5 Year Change | -42.01% |
| Change since IPO | -41.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| A061250 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 0.9% | -0.9% | 0.9% |
| 1Y | -39.2% | 7.7% | -3.4% |
Return vs Industry: A061250 underperformed the KR Pharmaceuticals industry which returned 7.7% over the past year.
Return vs Market: A061250 underperformed the KR Market which returned -3.4% over the past year.
Price Volatility
| A061250 volatility | |
|---|---|
| A061250 Average Weekly Movement | 7.2% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A061250 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A061250's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1974 | n/a | Joung-Kyu Lee | www.hwail.com |
Hwail Pharmaceutical Co.,Ltd. develops pharmaceutical raw materials in South Korea. It provides raw drug products, finished drug products, and functional health food raw material business.
Hwail Pharmaceutical Co.,Ltd. Fundamentals Summary
| A061250 fundamental statistics | |
|---|---|
| Market cap | ₩98.77b |
| Earnings (TTM) | ₩1.92b |
| Revenue (TTM) | ₩107.87b |
0.0x
P/E Ratio0.0x
P/S RatioIs A061250 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A061250 income statement (TTM) | |
|---|---|
| Revenue | ₩107.87b |
| Cost of Revenue | ₩93.79b |
| Gross Profit | ₩14.09b |
| Other Expenses | ₩12.16b |
| Earnings | ₩1.92b |
Last Reported Earnings
Mar 31, 2017
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A061250 perform over the long term?
See historical performance and comparison